Tizanidine Dosage and the Drug Interactions That Change It

Tizanidine is titrated from 2 mg up to a maximum of 36 mg a day, which is an eighteen fold range. Very few people reach the top of it, and the reason is rarely lack of effect. It is blood pressure, sedation and liver enzymes. Tizanidine also has the single most dramatic drug interaction of any common muscle relaxant: one antibiotic raises its blood levels tenfold. This guide covers the labelled titration and the interactions that decide whether you can use the drug at all.

The labelled titration schedule

The recommended starting dose is 2 mg by mouth every six to eight hours as needed, up to a maximum of three doses in 24 hours. That is 6 mg on day one. The dose can then be increased by 2 mg to 4 mg per dose every one to four days, based on clinical response and tolerability.

The maximum total daily dose is 36 mg. Single doses greater than 16 mg have never been studied, so 16 mg is the practical ceiling for any individual administration regardless of the daily total. Titration is deliberately slow because the hypotensive effect is largest early and dose escalation is the main way it is provoked.

Because the therapeutic effect is short lived, the label advises reserving treatment for the daily activities and times when relief of spasticity matters most. Tizanidine is designed to be timed rather than taken as continuous background cover. Available strengths here are Tizan 2mg and Trinex 2mg.

Liver enzyme monitoring before and during treatment

Tizanidine can cause hepatocellular liver injury, and the label puts monitoring instructions in the dosing section rather than burying them in warnings. Aminotransferase levels should be checked at baseline and again one month after the maximum dose is reached, or at any point hepatic injury is suspected.

If liver injury develops, the drug should be discontinued. In patients who already have hepatic impairment, the label directs lower individual doses during titration, and if higher doses become necessary, to increase the size of each dose rather than the number of doses per day. That distinction matters and is easy to get backwards.

Kidney impairment changes the dose too

In patients with creatinine clearance below 25 mL per minute, tizanidine clearance falls by more than half compared with healthy subjects of similar age. The practical effect is a longer duration of action from each dose.

The label handles this the same way as hepatic impairment: use lower individual doses during titration, and if higher doses are required, increase the individual dose rather than dosing more often. Spacing doses further apart is the safer lever in impaired clearance, because it is the accumulation between doses that causes trouble.

The interaction that rules the drug out

Tizanidine is metabolised almost entirely by CYP1A2, with about 95 percent of a dose metabolised and CYP1A2 the primary enzyme involved. That makes it exceptionally vulnerable to CYP1A2 inhibition. In ten healthy subjects given a single 4 mg dose, the effects were measured directly.

Co administered drug	Peak concentration change	Total exposure change	Half life change
Fluvoxamine	12 fold increase	33 fold increase	3 fold increase
Ciprofloxacin	7 fold increase	10 fold increase	Not reported

A 33 fold rise in exposure means a 2 mg dose behaves like a dose far outside anything ever tested. The consequences documented were significantly decreased blood pressure, increased drowsiness and increased psychomotor impairment. Both combinations are contraindicated outright, not merely cautioned.

Ciprofloxacin is the one that catches people, because it is a routine antibiotic for urinary and respiratory infections and nobody expects a short antibiotic course to interact seriously with a muscle relaxant. Anyone taking tizanidine who is prescribed ciprofloxacin needs the interaction flagged at the point of prescribing.

Moderate and weak CYP1A2 inhibitors to avoid

The label advises avoiding concomitant use with moderate or weak CYP1A2 inhibitors as well. The named list is long and includes drugs people take for years without thinking of them as interacting agents.

• Zileuton
• Antiarrhythmics: amiodarone, mexiletine, propafenone and verapamil
• Acid suppression: cimetidine and famotidine
• Oral contraceptives
• Acyclovir
• Ticlopidine

If one of these is clinically necessary and hypotension, bradycardia or excessive drowsiness appears, the tizanidine dose should be reduced or the drug stopped. Oral contraceptives get a separate paragraph in the label because the effect is quantified: women taking oral contraceptives had 50 percent lower tizanidine clearance than women who were not. Concomitant use is specifically not recommended.

Blood pressure and other alpha 2 agonists

Tizanidine is an alpha 2 adrenergic agonist, so lowering blood pressure is a direct extension of how it works rather than an unexpected side effect. Syncope has been reported after marketing. Risk is minimised by slow titration and by checking for symptoms of low blood pressure before each dose increase.

Two combinations compound the problem. Other alpha 2 adrenergic agonists such as clonidine should not be used with tizanidine because the hypotensive effects are cumulative. Antihypertensive medicines produce additive lowering, so anyone on blood pressure treatment needs monitoring. Moving from lying down to standing raises the risk of orthostatic symptoms, so getting up slowly matters during titration.

Take it consistently with or without food

Food changes tizanidine absorption, and it changes it differently depending on whether you take tablets or capsules. This is one of the few muscle relaxants where the tablet and capsule are genuinely not interchangeable under real conditions.

Form and condition	Peak concentration	Time to peak	Extent of absorption
Tablet or capsule, fasting	Reference	1 hour	Reference
Tablet with food	Up around 30 percent	1 hour 25 minutes	Up around 30 percent
Capsule with food	Down around 20 percent	Delayed 2 to 3 hours	Up around 10 percent

Tablets and capsules are bioequivalent while fasting but not when taken with food. A fed tablet delivers a peak roughly 50 percent higher than a fed capsule. The label therefore recommends consistent administration with respect to food, and monitoring for either loss of effect or new side effects if you switch between forms or between fed and fasted dosing.

A worked titration over the first four weeks

The label gives a rule rather than a schedule, so it helps to see what the rule looks like in practice. The pattern below follows the labelled instruction to increase by 2 mg to 4 mg per dose every one to four days, using the slower end of that range because it is better tolerated. Actual titration should follow your prescriber.

Period	Dose per administration	Doses per day	Total daily dose
Days 1 to 4	2 mg	Up to 3	Up to 6 mg
Days 5 to 8	4 mg	Up to 3	Up to 12 mg
Days 9 to 14	6 mg	Up to 3	Up to 18 mg
Days 15 to 21	8 mg	Up to 3	Up to 24 mg
Week 4 onward	Up to 12 mg	Up to 3	Up to 36 mg

Three checkpoints matter along the way. Before each step up, check for symptoms of low blood pressure such as light headedness on standing, and hold the current dose if they are present. At the point the maximum dose is reached, arrange the one month liver enzyme check the label calls for. And at every stage, remember that the number of doses per day stays capped at three, so escalation happens by making each dose larger rather than by taking the drug more often.

Most people stop climbing well before 36 mg. The dose that controls spasticity without unacceptable drowsiness or blood pressure drop is the right dose, and there is no benefit in pushing toward the ceiling once that point is reached. If tizanidine is being used off label for acute musculoskeletal spasm rather than for spasticity, the practical range is usually much lower and the course much shorter than this schedule suggests, closer to the two to three week limits that apply to the antispasmodic agents covered in our cyclobenzaprine dosage guide.

Sedation and how it behaves over time

Tizanidine causes sedation that can interfere with everyday activity. The label makes a useful observation about its time course: in multiple dose studies, the proportion of patients with sedation peaked after the first week of titration and then stayed stable through the maintenance phase.

That means the worst sedation is generally an early titration phenomenon rather than something that accumulates. It is a reason to persist through week one at a given dose before deciding the drug is unusable, and a reason to be strict about not driving during that first week. Sedative effects are additive with alcohol, benzodiazepines, opioids and tricyclic antidepressants.

Hallucinations are a documented effect

Formed visual hallucinations or delusions were reported in 5 of 170 patients, around 3 percent, across two North American controlled studies. Most patients were aware the events were not real. One developed psychosis alongside the hallucinations, and one continued to have problems for at least two weeks after stopping.

Hallucinations have also been reported after marketing. The label advises considering discontinuation in patients who develop them. This is worth knowing in advance, because a 3 percent rate is high enough to be encountered and people who do not expect it often do not connect it to the medicine.

Stopping tizanidine needs a taper

Tizanidine causes withdrawal reactions including rebound hypertension, tachycardia and hypertonia. The label directs reducing the dose by 2 mg to 4 mg per day when discontinuing.

Care is particularly needed in two groups: anyone who has been on high doses of 20 mg to 28 mg daily for nine weeks or longer, and anyone also taking opioids. Rebound hypertension after abrupt cessation of an alpha 2 agonist is the same mechanism seen with clonidine withdrawal, and it can be clinically significant.

What tizanidine is and is not good for

Tizanidine is licensed for spasticity, meaning increased muscle tone from upper motor neuron damage in conditions such as multiple sclerosis and spinal cord injury. It is used off label for acute musculoskeletal spasm, and there is fair evidence from a systematic review of 101 randomised trials that it beats placebo for musculoskeletal conditions as well.

The same review found baclofen and tizanidine roughly equivalent for efficacy in spasticity, with similar overall adverse event rates but a different pattern: tizanidine produces more dry mouth and baclofen produces more weakness. A 2024 review of long term muscle relaxant use, in which tizanidine featured in 8 of 44 studies, found benefit for painful spasms or cramps and neck pain but not for low back pain, fibromyalgia or headache. If baclofen is the better fit, strengths available include Liofen 10mg and Liofen 25mg.

Safety information

Tizanidine is prescription only in the United States, United Kingdom, Australia and Canada. It does not treat the cause of spasticity and works alongside physiotherapy rather than instead of it. Do not combine it with alcohol. Tell your prescriber if you take ciprofloxacin, fluvoxamine, an oral contraceptive, an antiarrhythmic, cimetidine, famotidine or any blood pressure medicine, and if you have liver or kidney disease. Do not stop abruptly after prolonged or high dose use. For how tizanidine compares with the alternatives, see our muscle relaxer comparison guide, and browse the wider chronic pain treatment range.

References

• FDA prescribing information, tizanidine hydrochloride tablets: sections 2.1 to 2.6 dosage and administration, 5.1 to 5.6 warnings and precautions, 7.1 to 7.6 drug interactions and 12.1 to 12.3 clinical pharmacology
• DailyMed label, tizanidine hydrochloride: indications, contraindications and description sections
• Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. PMID 15276195
• Long term use of muscle relaxant medications for chronic pain: a systematic review. PMID 39298168
• Pharmacotherapy for spine related pain in older adults. PMID 35754070